The trial will evaluate pirfenidone capsules for the treatment of radiation-induced lung injury (RILI), with or without immune-related pneumonitis (CIP). This regulatory milestone marks the ...

The trial will evaluate pirfenidone capsules for the treatment of radiation-induced lung injury (RILI), with or without immune-related pneumonitis (CIP). This regulatory milestone marks the expansion ...

Announcing a new article publication for BIO Integration journal. Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Eric Cannon, PharmD, FAMCP, discusses how precision medicine advancements and biomarker development can enable targeted ...

A recent publication by the British Thoracic Society offers the first long-term analysis of the UK Idiopathic Pulmonary ...

Gyre Therapeutics, Inc.’s GYRE share price has dipped by 14.60%, which has investors questioning if this is right time to buy ...

Eric Cannon, PharmD, FAMCP, discusses how LPA1 receptor activation promotes fibrosis in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) through myofibroblast ...

Despite the introduction of nintedanib and pirfenidone for therapy of some fibrotic lung diseases, pulmonary fibrosis can remain challenging to effectively treat. This is in part because lung ...

Despite the introduction of nintedanib and pirfenidone for therapy of some fibrotic lung diseases, pulmonary fibrosis can remain challenging to effectively treat. This is in part because lung ...